Why did the company hide Alzheimer's new drug?

When the American company Pfizer, who made medicines in January last year, announced a new drug for diseases like Alzheimer and Perkinson, there was frustration between patients and researchers.

Earlier, the company had spent millions of dollars on finding alternative medicine for Alzheimer's. But then they decided that this money would be spent elsewhere.

Pfizer rightly said that we should put this expenditure there where the strength of our scientists is strong.

But according to a report in the American newspaper Washington Post, the company hid the results of this research, while these results were very important in the fight against Alzheimer's.

Why this is so, it is also difficult to understand because mental health is now being considered as a big challenge for the medical world.

This study was done on hundreds of insurance claims, which showed that a drug of the Pfizer - 'Enbrel', which is used to treat rheumatoid arthritis, is to reduce the risk of Alzheimer's by 64 Could reduce up to five percent.

In a presentation of an inner committee of the Fishers in 2018, it was stated that "Enbrel could stop Alzheimer's, reduce its cure and speed of growth."

In the talks with the Washington Post, the company confirmed that these results were not made public.

According to the newspaper, "The company said that in three years of internal review it was found that Enbrel was not effective in the treatment of Alzheimer's because the drug does not reach the brain tissue directly."

Pfizer said that unlike Alzheimer's, this drug's clinical trials were less likely to succeed.

"wrong way"
According to the Washington Post, "Pfizer said that he did not make the results of his research public because it could mislead other scientists working to find Alzheimer's second drug."

Some dignified scientists have also been cited in this news. Professor Rudolf E. Tanzi of Harvard Medical School, who is researching Alzheimer's, said, "Absolutely he had to do it."

Another researcher from Alzheimer's Professor Kennon Walker at Johns Hopkins University said, "This information is very useful for scientists. Whether information is positive or negative, we help in making better decisions."

The fisher surely knows that sometimes the medicine created for a disease turns out to be more effective in the treatment of other diseases. This has happened in connection with Viagra.